A Phase 2 interventional study of Adavosertib in Advanced Lymphoma, Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment
Kummar S, Song Z, Reiss KA, Ford JM, Chen L, Rolig AS, Zwiebel JA, Gore SD, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Gross J, Brunnquell D, Jackso…PubMed 42308463 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI) — 12 open to participants now, 33 under way, none of them phase 3. Hematologic Neoplasms · National Cancer Institute (NCI).
Among the 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI), this one is the 33rd largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2017, is one of 31 in phase 2, reaches primary completion later than 6 of the 32 other live ones, and was the 29th registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →12 of the 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 18–75
National Cancer Institute (NCI) · Sites in United States
Ages 12–120 · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 12–120 · Healthy volunteers
By country, each count listing its studies:
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 39
First in 1995; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 38 across the 52 interventional studies, 88 across the 7 observational. Of the 23 that completed or were terminated, 13 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
4 of the studies in Hematologic Neoplasms by National Cancer Institute (NCI) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT04959175National Cancer Institute (NCI)Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | 2027-04-27 |
| NCT05436418National Cancer Institute (NCI)The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation | 2027-06-25 |
| NCT05470491National Cancer Institute (NCI)Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI), from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation. AZD1775 may block a protein called WEE1, which may be needed for growth of cancer cells that express BRCA mutations. Researchers hope to learn if AZD1775 will shrink this type of cancer or stop its growth.
PRIMARY OBJECTIVE:
I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.
SECONDARY OBJECTIVES:
I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma.
II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms.
IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens.
OUTLINE:
Patients receive adavosertib (AZD1775) orally (PO) once daily (QD) on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months if less than 2 years from study entry, and then every 6 months for an additional year from study entry.
THE MATCH SCREENING TRIAL:
Please see NCT02465060 for information on the MATCH Screening Protocol and applicable documents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive adavosertib PO QD on days 1-5 and 8-12 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: Adavosertib
Given PO
Also known as: AZD 1775, AZD-1775, AZD1775, MK 1775, MK-1775, MK1775
Objective Response Rate (ORR)
ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.
Time frame: Tumor assessments occurred at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
6-month Progression-Free Survival (PFS)
Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro- Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.
Time frame: Assessed at baseline, then every 3 cycles for the first 33 cycles, and every 4 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined
Progression-free Survival
PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.
Time frame: Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
Subprotocol Z1I was activated on March 13, 2017. Thirty-three patients were enrolled on EAY131-Z1I between March 24, 2017, and August 9, 2017.
| Milestone | Treatment (Adavosertib) |
|---|---|
| Started | 33 |
| Started protocol therapy | 33 |
| Eligible and treated | 30 |
| Completed | 0 |
| Not completed | 33 |
| Withdrew: Ineligible | 3 |
| Withdrew: Adverse event | 4 |
| Withdrew: Death | 1 |
| Withdrew: Disease progression | 19 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Physician decision | 1 |
ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.
| percentage of participants | Treatment (Adavosertib) |
|---|---|
| Objective Response Rate (ORR) | 3.3 (0.2 to 14.9) |
Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro- Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.
| percentage of participants | Treatment (Adavosertib) |
|---|---|
| 6-month Progression-Free Survival (PFS) | 23.4 (10.7 to 36.2) |
PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.
| months | Treatment (Adavosertib) |
|---|---|
| Progression-free Survival | 2.0 (1.5 to 2.1) |
Collected over Assessed every 21 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment (Adavosertib) | 27/33 (81.8%) | 18/33 (54.5%) | 26/33 (78.8%) |
| Event | Treatment (Adavosertib) |
|---|---|
| Neutrophil count decreasedInvestigations | 7/33 |
| FatigueGeneral disorders | 4/33 |
| NauseaGastrointestinal disorders | 4/33 |
| Platelet count decreasedInvestigations | 4/33 |
| White blood cell decreasedInvestigations | 4/33 |
| HyperglycemiaMetabolism and nutrition disorders | 4/33 |
| AnemiaBlood and lymphatic system disorders | 3/33 |
| VomitingGastrointestinal disorders | 3/33 |
| HypophosphatemiaMetabolism and nutrition disorders | 3/33 |
| DiarrheaGastrointestinal disorders | 2/33 |
| Event | Treatment (Adavosertib) |
|---|---|
| FatigueGeneral disorders | 17/33 |
| DiarrheaGastrointestinal disorders | 15/33 |
| NauseaGastrointestinal disorders | 13/33 |
| AnemiaBlood and lymphatic system disorders | 12/33 |
| Aspartate aminotransferase increasedInvestigations | 8/33 |
| HypoalbuminemiaMetabolism and nutrition disorders | 8/33 |
| VomitingGastrointestinal disorders | 7/33 |
| Alkaline phosphatase increasedInvestigations | 7/33 |
| White blood cell decreasedInvestigations | 7/33 |
| HyperglycemiaMetabolism and nutrition disorders | 7/33 |
Patients who were eligible and started protocol therapy were the analyzable patients
| Age, Continuous(years) | Treatment (Adavosertib) |
|---|---|
| Median | 61.5 (36 to 79) |
| Sex: Female, Male(Participants) | Treatment (Adavosertib) |
|---|---|
| Female | 19 |
| Male | 11 |
| Ethnicity (NIH/OMB)(Participants) | Treatment (Adavosertib) |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 27 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Treatment (Adavosertib) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 23 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in May 2020, 38 months.
Results were first posted in Oct 2026, 6 years 4 months after primary completion.
Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's 38 months is below that.
Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Kummar S, Song Z, Reiss KA, Ford JM, Chen L, Rolig AS, Zwiebel JA, Gore SD, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Gross J, Brunnquell D, Jackso…PubMed 42308463 ↗
Kummar S, Song Z, Reiss KA, Ford JM, Chen L, Rolig AS, Zwiebel JA, Gore SD, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Gross J, Brunnquell D, Jackso…PubMed 42308463 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adavosertib
National Cancer Institute (NCI) →